On the other hand, the intestinal epithelial deletion of SPHK1 prevents colitis-associated cancer development in mice [56], SPHK inhibitor treatment resulted in a dose-dependent decrease in colitis-driven colon cancer in mice [57], and SPHK1 knockout mice demonstrated a lower incidence of colon cancer development in murine model [24]. Here, SPHK1 is linked to malignant colon neoplasm.